MBIO

Mustang Bio, Inc.

1.31 USD
+0.06 (+4.80%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Mustang Bio, Inc. stock is down -5.76% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 14.29% of the previous 6 February’s closed higher than January.

About Mustang Bio, Inc.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition.